The option value of innovative treatments for non-small cell lung cancer and renal cell carcinoma.
CONCLUSIONS: Option value is important when valuing therapies like nivolumab that extend life in a rapidly evolving area of care.
PMID: 29087638 [PubMed - in process]
Source: The American Journal of Managed Care - Category: Health Management Authors: Thornton Snider J, Batt K, Wu Y, Tebeka MG, Seabury S Tags: Am J Manag Care Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Clinical Trials | Epidemiology | Health Management | Kidney Cancer | Lung Cancer | Managed Care | Non-Small Cell Lung Cancer | Renal Cell Carcinoma | Study